Patents by Inventor Jens Damsgaard Mikkelsen
Jens Damsgaard Mikkelsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180362611Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: April 11, 2018Publication date: December 20, 2018Inventors: Bjarne Due LARSEN, Jens Damsgaard MIKKELSEN, Søren NEVE
-
Publication number: 20170107267Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: June 15, 2016Publication date: April 20, 2017Inventors: Bjarne Due LARSEN, Jens Damsgaard MIKKELSEN, Søren NEVE
-
Patent number: 8372832Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: March 14, 2012Date of Patent: February 12, 2013Assignee: Neurosearch A/SInventors: Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Patent number: 8343960Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: November 13, 2008Date of Patent: January 1, 2013Assignee: Neurosearch A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Ostergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20120288443Abstract: The present invention relates to certain labelled pyrrolyl-oxadizolyl-diazabicyclononane derivatives. Furthermore, the present invention relates to the use of said derivatives in their labelled form in diagnostic methods, in particular for in vivo receptor imaging (neuroimaging).Type: ApplicationFiled: November 9, 2010Publication date: November 15, 2012Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Jens Damsgaard Mikkelsen, Anders Janusz Ettrup
-
Publication number: 20120172353Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: March 14, 2012Publication date: July 5, 2012Inventors: Dan PETERS, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Patent number: 8158619Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: GrantFiled: May 29, 2007Date of Patent: April 17, 2012Assignee: Neurosearch A/SInventors: Dan Peters, Gunnar M. Olsen, Elsebet ØStergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jen Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Publication number: 20110245165Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: April 29, 2010Publication date: October 6, 2011Inventors: Bjarne Due LARSEN, Jens Damsgaard Mikkelsen, Søren Neve
-
Publication number: 20110144008Abstract: Novel peptide agonists of GLP-1 activity useful for lowering blood glucose levels. The novel peptides comprise variants of the GLP-1 or the exendin-4 polypeptide sequence and are pharmacologically active and stable. These peptides are useful in the treatment of diseases that benefit from regulation of excess levels of blood glucose and/or regulation of gastric emptying, such as diabetes and eating disorders.Type: ApplicationFiled: December 1, 2010Publication date: June 16, 2011Inventors: Bjarne Due LARSEN, Jens Damsgaard Mikkelsen, Søren Neve
-
Publication number: 20110118304Abstract: A method for treating over-eating disorders, in particular Bulimia nervosa, Binge Eating Disorder (BED), and Compulsive Over-Eating. The invention furthermore relates to novel pharmaceutical compositions for the treatment of over-eating disorders comprising a therapeutically effective amount of a compound of formula I.Type: ApplicationFiled: November 19, 2008Publication date: May 19, 2011Applicant: NeuroSearch A/SInventors: Jens Damsgaard Mikkelsen, Naheed Mirza
-
Publication number: 20110112078Abstract: This invention relates to novel oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholin receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: June 9, 2009Publication date: May 12, 2011Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Ostergaard Nielsen, Gunnar M. Olsen, Philip K. Ahring, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20110112119Abstract: This invention relates to novel azabicyclooctyl-quinazolinone derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: June 9, 2009Publication date: May 12, 2011Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, Philip K. Ahring, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20110046118Abstract: This invention relates to novel 1,4-diaza-bicyclo [3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: November 13, 2008Publication date: February 24, 2011Applicant: Neurosearch A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20100317572Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a compound of Formula I and an anti-obesity compound. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for combating obesity or an obesity associated disease.Type: ApplicationFiled: December 18, 2008Publication date: December 16, 2010Applicant: NeuroSearch A/SInventor: Jens Damsgaard Mikkelsen
-
Publication number: 20100305108Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: November 13, 2008Publication date: December 2, 2010Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20100298307Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidine derivatives of formula (I) and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: November 13, 2008Publication date: November 25, 2010Applicant: NEUROSEARCH A/SInventors: Dan Peters, Daniel B. Timmermann, Elsebet Østergaard Nielsen, Gunnar M. Olsen, Tino Dyhring, Jeppe Kejser Christensen, John Paul Redrobe, Jens Damsgaard Mikkelsen
-
Publication number: 20100216780Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: May 29, 2007Publication date: August 26, 2010Inventors: Dan Peters, Gunnar M. Olsen, Elsebet Østergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Björk Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Timo Dyhring
-
Publication number: 20090197872Abstract: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.Type: ApplicationFiled: May 29, 2007Publication date: August 6, 2009Inventors: Dan Peters, Gunnar M. Olsen, Elsebet Ostergaard Nielsen, Daniel B. Timmermann, Steven Charles Loechel, Jens Damsgaard Mikkelsen, Henrik Bjork Hansen, John Paul Redrobe, Jeppe Kejser Christensen, Tino Dyhring
-
Publication number: 20040259777Abstract: The present invention relates generally to the control of metabolic disorders, such as body weight disorders, of animals including mammals and humans, and more particularly to polypeptides identified herein as modulators of metabolic disorders, and to diagnostic and therapeutic uses of such modulators. In its broadest aspect, the present invention relates to mammalian neuronatin proteins sequences, isoforms thereof, and degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian metabolism and that have been postulated to play a critical role in the regulation of body weight, adiposity and non-insulin dependent diabetes mellitus (NIDDM). The invention further relates to the preparation of the modulators of the invention.Type: ApplicationFiled: December 4, 2003Publication date: December 23, 2004Inventors: Kenneth Thirstrup, Jens Damsgaard Mikkelsen, Niels Vrang, Leif Kongskov Larsen, Mads Tang-Christensen
-
Patent number: RE45313Abstract: The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.Type: GrantFiled: July 17, 2013Date of Patent: December 30, 2014Assignee: Zealand Pharma A/SInventors: Bjarne Due Larsen, Jens Damsgaard Mikkelsen, Søren Neve